Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia

被引：2
|
作者：
El Kinge, Abdul Rahman
Hatourn, Hassan A.
Mahfouz, Rami A. [2 ]
Otrock, Zaher K. [2 ]
Jabbour, Elias [3 ]
Kantarjian, Hagop [3 ]
Bazarbachi, Ali [1 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Bone Marrow Transplantat Program, Beirut, Lebanon
[2] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Beirut, Lebanon
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期
关键词：
ACUTE MYELOGENOUS LEUKEMIA; RELAPSE; CHEMOTHERAPY; PROPOSAL;
D O I：
10.1016/j.leukres.2008.05.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：565 / 566
页数：2
相关论文
共 50 条
  • [41] A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia
    Quann, Kevin
    Lontos, Konstantinos
    Sehgal, Alison
    Raptis, Anastasios
    Im, Annie
    Redner, Robert L.
    Dorritie, Kathleen A.
    Agha, Mounzer
    Hou, Jing-Zhou
    Farah, Rafic
    Rossetti, James
    Normolle, Daniel P.
    Whiteside, Theresa L.
    Hsu, Yen-Michael Sheng
    Boyiadzis, Michael
    HAEMATOLOGICA, 2024, 109 (12) : 4106 - 4111
  • [42] Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
    Fenwarth, Laurene
    Fournier, Elise
    Cheok, Meyling
    Boyer, Thomas
    Gonzales, Fanny
    Castaigne, Sylvie
    Boissel, Nicolas
    Lambert, Juliette
    Dombret, Herve
    Preudhomme, Claude
    Duployez, Nicolas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 21
  • [43] Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
    Fournier, Elise
    Duployez, Nicolas
    Ducourneau, Benoit
    Raffoux, Emmanuel
    Turlure, Pascal
    Caillot, Denis
    Thomas, Xavier
    Marceau-Renaut, Alice
    Chantepie, Sylvain
    Malfuson, Jean-Valere
    Lemasle, Emilie
    Cheok, Meyling
    Celli-Lebras, Karine
    Guerin, Estelle
    Terre, Christine
    Lambert, Juliette
    Pautas, Cecile
    Dombret, Herve
    Castaigne, Sylvie
    Preudhomme, Claude
    Boissel, Nicolas
    BLOOD, 2020, 135 (08) : 542 - 546
  • [44] The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
    Pagano, L.
    Fianchi, L.
    Caira, M.
    Rutella, S.
    Leone, G.
    ONCOGENE, 2007, 26 (25) : 3679 - 3690
  • [45] Gemtuzumab ozogamicin in acute myeloid leukaemia
    Ravandi, Farhad
    Kantarjian, Hagop
    NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (06) : 310 - 311
  • [46] Conventional post-remission therapy in adult acute myeloid leukemia - a systematic review/meta-analysis
    Magina, N.
    Pregartner, G.
    Berghold, A.
    Sill, H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S385 - S385
  • [47] Gemtuzumab ozogamicin in acute myeloid leukaemia
    Farhad Ravandi
    Hagop Kantarjian
    Nature Reviews Clinical Oncology, 2012, 9 : 310 - 311
  • [48] Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg®) therapy of acute myeloid leukemia
    Leopold, LH
    Berger, MS
    Feingold, J
    CLINICAL LYMPHOMA, 2002, 2 : S29 - S34
  • [49] Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia
    Sousa, AB
    Fernandes, JP
    Costa, I
    Ferreira, G
    Nunes, O
    Ribeiro, P
    Neves, A
    Cruz, E
    Aveiro, F
    Rodrigues, AS
    Bernardo, M
    Conduto, A
    Goncalves, AJ
    Monteiro, A
    Sousa, M
    Soares, VH
    Veiga, J
    Gouveia, J
    HEMATOLOGY AND CELL THERAPY, 1998, 40 (02): : 63 - 66
  • [50] The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia
    Kell, Jonathan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 377 - 382
12345